 |
 |
 |
Nplate® (romiplostim) REMS Program (Nplate® NEXUS Program): Elimination of Prescriber, Institution, and Patient Enrollment requirements to prescribe and receive Nplate®.
Please see prescribing information for serious risks associated with Nplate® therapy
Amgen is no longer accepting data for the Nplate® NEXUS program. The nplatenexus.com patient management pages and Nplate® NEXUS fax (1-877-Nplate0) have been deactivated. To report a SUSPECTED ADVERSE REACTION to Amgen Inc., please call 1-800-772-6436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
